ArticleCardiovascular drugs and therapy2026
Vps16 Attenuates Myocardial Ischemia/reperfusion Injury by Interacting with UVRAG and Activating Rab7.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Purpose:Vacuolar protein sorting associated protein 16 (Vps16) is a key component of the Vps core complex (Vps–C) and acts as a tethering protein in membrane fusion. Nevertheless, its role in myocardial ischemia/reperfusion (I/R) remains largely unexplored. Methods:This study established a myocardial I/R model in rats and a hypoxia/reoxygenation (H/R) model using H9c2 cells. Both gain-of-function (via adenovirus-mediated Vps16 overexpression) and loss-of-function (via shRNA-mediated Vps16 knockdown) experiments were conducted. Results:This study showed that Vps16-overexpression improved autophagic flux and cardiac function following I/R in vivo and in vitro. However, the protective effect of Vps16 on cardiomyocytes against I/R injury was nullified when treated with autophagy inhibitors such as Bafilomycin A1 (BafA1). Vps16-knockdown worsened H/R-induced impairment of autophagic flux and cell death in H9c2 cardiomyocytes, while these effects could be reversed by rapamycin (Rapa), an autophagy activator. Mechanistically, Vps16 competed with Rubicon for binding to UVRAG in cardiomyocytes via the residues 333–613, subsequently promoting Rab7 activation, which is essential for the late stage of autophagy. Knockdown of Rubicon successfully mitigated the adverse impact of truncated Vps16 (lacking residues 333–613) in cardiomyocytes. Conclusion:These findings indicate that Vps16 exerts a protective effect against myocardial I/R injury, achieved by promoting autolysosome maturation of and reinstating the autophagic flux in cardiomyocytes.
Indexed as
Identifiers
41854796What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.